Dynamic Estimates of Survival in Oncocytic Cell Carcinoma of the Thyroid

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2023 Nov 29

PMID 38030805

Authors

Yang Shi

Yuenan Zheng

Hao Zhang

Wenwu Dong

Ping Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Little is known about death hazard and conditional survival of oncocytic cell carcinoma of the thyroid (OCC).

Methods: Patients diagnosed with OCC between 2004 to 2019 were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. The Kaplan-Meier method was used to estimate the actuarial disease-specific survival (DSS). The annual hazard rate of death was depicted employing the hazard function. Based on the life-table method, the conditional DSS was calculated.

Results: In terms of DSS rates, there were statistically significant differences among the different stages (P < 0.01). Annual hazard curves for mortality from OCC in the entire study participants demonstrated an overall decreasing tendency with two peaks at 3 and 10 years. In patients with distant disease, the death risk curve was the steepest and decreased quickly and evidently. Conditional DSS tended to increase over time in the entire study population. Patients with distant disease showed more significant alterations than those patients with local or regional disease.

Conclusions: Prognosis improved over time in patients with OCC. The largest increase in conditional DSS was observed in patients with distant disease. Conditional survival may provide more relevant prognostic information than conventional survival estimates and allow personalized follow-up and counseling.

Citing Articles

Conditional survival and changing risk profile in patients with gliosarcoma.

Xu L, Yang Z, Chen H, Sun C, Tu C, Gu Z Front Med (Lausanne). 2024; 11:1443157.

PMID: 39309681 PMC: 11412853. DOI: 10.3389/fmed.2024.1443157.

References

Oluic B, Paunovic I, Loncar Z, Djukic V, Diklic A, Jovanovic M . Survival and prognostic factors for survival, cancer specific survival and disease free interval in 239 patients with Hurthle cell carcinoma: a single center experience. BMC Cancer. 2017; 17(1):371. PMC: 5445517. DOI: 10.1186/s12885-017-3370-x. View

Panunzio A, Barletta F, Tappero S, Garcia C, Piccinelli M, Incesu R . Contemporary conditional cancer-specific survival rates in surgically treated adrenocortical carcinoma patients: A stage-specific analysis. J Surg Oncol. 2022; 127(4):560-567. DOI: 10.1002/jso.27161. View

Wang P, Sun Z, Wang W, Deng J, Wang Z, Liang H . Conditional survival of patients with gastric cancer who undergo curative resection: A multi-institutional analysis in China. Cancer. 2017; 124(5):916-924. DOI: 10.1002/cncr.31160. View

Hagens E, Feenstra M, Eshuis W, Hulshof M, van Laarhoven H, van Berge Henegouwen M . Conditional survival after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer. Br J Surg. 2020; 107(8):1053-1061. PMC: 7317937. DOI: 10.1002/bjs.11476. View

Petric R, Gazic B, Besic N . Prognostic factors for disease-specific survival in 108 patients with Hürthle cell thyroid carcinoma: a single-institution experience. BMC Cancer. 2014; 14:777. PMC: 4213470. DOI: 10.1186/1471-2407-14-777. View

Ploussard G, Shariat S, Dragomir A, Kluth L, Xylinas E, Masson-Lecomte A . Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time. Eur Urol. 2013; 66(2):361-70. DOI: 10.1016/j.eururo.2013.09.050. View

Haigh P, Urbach D . The treatment and prognosis of Hürthle cell follicular thyroid carcinoma compared with its non-Hürthle cell counterpart. Surgery. 2005; 138(6):1152-7. DOI: 10.1016/j.surg.2005.08.034. View

Coca-Pelaz A, Rodrigo J, Shah J, Sanabria A, Al Ghuzlan A, Silver C . Hürthle Cell Carcinoma of the Thyroid Gland: Systematic Review and Meta-analysis. Adv Ther. 2021; 38(10):5144-5164. DOI: 10.1007/s12325-021-01876-7. View

Baloch Z, Asa S, Barletta J, Ghossein R, Juhlin C, Jung C . Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol. 2022; 33(1):27-63. DOI: 10.1007/s12022-022-09707-3. View

10.

Nagar S, Aschebrook-Kilfoy B, Kaplan E, Angelos P, Grogan R . Hurthle cell carcinoma: an update on survival over the last 35 years. Surgery. 2013; 154(6):1263-71. DOI: 10.1016/j.surg.2013.06.029. View

11.

Humphreys B, Memeh K, Funkhouser A, Vaghaiwalla T . Prognostic factors and survival analysis of Hurthle cell carcinoma: A population-based study. Surgery. 2022; 172(5):1379-1384. DOI: 10.1016/j.surg.2022.07.007. View

12.

Wenter V, Albert N, Unterrainer M, Ahmaddy F, Ilhan H, Jellinek A . Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2020; 48(2):449-460. PMC: 7835150. DOI: 10.1007/s00259-020-04952-2. View

13.

Chindris A, Casler J, Bernet V, Rivera M, Thomas C, Kachergus J . Clinical and molecular features of Hürthle cell carcinoma of the thyroid. J Clin Endocrinol Metab. 2014; 100(1):55-62. DOI: 10.1210/jc.2014-1634. View

14.

Kang M, Kim H, Jeong C, Kwak C, Kim H, Ku J . Conditional Survival and Associated Prognostic Factors in Patients with Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy: A Retrospective Study at a Single Institution. Cancer Res Treat. 2015; 48(2):621-31. PMC: 4843715. DOI: 10.4143/crt.2015.220. View

15.

Dong W, Okamoto T, Ji X, Xiang J, Zhang D, Zhang P . Conditional Survival Rate Estimates for Anaplastic Thyroid Cancer Beyond the First Year: An Analysis of SEER Data (2004-2019). Thyroid. 2022; 33(4):523-526. DOI: 10.1089/thy.2022.0339. View

16.

Wang J, Huang X, Sun S, Wang K, Qu Y, Chen X . Stage-dependent conditional survival and failure hazard of non-metastatic nasopharyngeal carcinoma after intensity-modulated radiation therapy: Clinical implications for treatment strategies and surveillance. Cancer Med. 2021; 10(11):3613-3621. PMC: 8178506. DOI: 10.1002/cam4.3917. View

17.

Zhou X, Zheng Z, Chen C, Zhao B, Cao H, Li T . Clinical characteristics and prognostic factors of Hurthle cell carcinoma: a population based study. BMC Cancer. 2020; 20(1):407. PMC: 7216584. DOI: 10.1186/s12885-020-06915-0. View

18.

Dong W, Horiuchi K, Tokumitsu H, Sakamoto A, Noguchi E, Ueda Y . Time-Varying Pattern of Mortality and Recurrence from Papillary Thyroid Cancer: Lessons from a Long-Term Follow-Up. Thyroid. 2019; 29(6):802-808. DOI: 10.1089/thy.2018.0128. View

19.

Lopez-Penabad L, Chiu A, Hoff A, Schultz P, Gaztambide S, Ordonez N . Prognostic factors in patients with Hürthle cell neoplasms of the thyroid. Cancer. 2003; 97(5):1186-94. DOI: 10.1002/cncr.11176. View

20.

Mills S, Haq M, Smellie W, Harmer C . Hürthle cell carcinoma of the thyroid: Retrospective review of 62 patients treated at the Royal Marsden Hospital between 1946 and 2003. Eur J Surg Oncol. 2008; 35(3):230-4. DOI: 10.1016/j.ejso.2008.06.007. View